Does Sequenom Inc (NASDAQ:SQNM) has alternatives?

Posted by Lynn Eisler September 25, 2013 0 Comment 2267 views

Sequenom, Inc (NASDAQ:SQNM) announced that its Directors has given the go-ahead for the review of some potential strategic alternatives for the company’s genetic analysis business. Jeffries LLC will be the financial advisor who will assist in evaluating the alternatives. Sequenom, Inc (NASDAQ:SQNM) has not yet made any specific decision to get into any kind of transaction at this point of time. Another point is that Sequenom, Inc (NASDAQ:SQNM) has not guaranteed that it will enter any similar transaction in the future either. The company chooses not to disclose any details about the strategic alternatives to its review processes right now.

Tuesday’s trading

In Tuesday’s trading session, Sequenom, Inc (NASDAQ:SQNM) stock dropped 2.57%. The shares opened at a price of $2.82 which rose to an intraday high of $2.85 and dipped to a close of $2.69. Approximately 4.78 million shares were traded on Tuesday and an average volume of 2.24 million shares were traded over 30 days. The 52-week low of the shares is $2.58 and the 52-week high is $5.36. The company has a market cap of $310.33 billion.

The company

Sequenom, Inc (NASDAQ:SQNM) is a molecular diagnostic-testing and genetics-analysis company. It is committed to providing molecular diagnostic-testing services, and research-use-only services, products, genetic analysis, applications and products that turn results of genomic-science into solutions used in biomedical research, translational-research, molecular-medicine applications, and livestock, agricultural, and various areas of research.

Its efforts in development and commercialization in different diagnostic areas include prenatal-diagnostics, non-invasive women’s health, ophthalmology, and medical conditions like infectious diseases, oncology and autoimmunity. Sequenom, Inc (NASDAQ:SQNM) operates in 2 segments: Molecular Diagnostics and Genetic Analysis. Sequenom, Inc (NASDAQ:SQNM) is in competition with Verinata Health, Ikonysis, Aria Diagnostics, Celula, Fluidigm Corp., Beckman Coulter, Natera, Life Technologies, Illumina Inc., Biotage AB, Fluidigm, Ibis Biosciences, KBiosystems and Luminex.

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment